Health
J&J’s COVID-19 vaccine 66 per cent effective in trial – The Tribune India
The vaccine is 85 per cent effective in stopping severe disease and preventing hospitalisation
January 29
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large trial against multiple variants across three continents.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.
A high bar has been set by two authorised vaccines from Pfizer/BioNTech and Moderna,…
-
Noosa News12 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News13 hours agoMotorcyclist dies in crash with truck
-
Noosa News13 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General18 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging